Business
Cardax Reports Q2 2017 Results
Cardax Reports Q2 2017 Results.
About this update from Cardax Inc
[{"type":"text","content":"\n \n Cardax, Inc. (OTCQB:CDXI) reported June 30, 2017 results today.\n \n \n Cardax announced today that its revenues from ZanthoSyn™ were more than \n $170,000 during the first half of 2017. Revenues in the second quarter \n do not reflect the purchase order received this month from General \n Nutrition Corporation (“GNC”) to stock ZanthoSyn™, Cardax’s safe, \n physician friendly astaxanthin dietary supplement for inflammatory \n health and longevity, in all of the more than 3,200 GNC corporate stores \n nationwide. As a result, third quarter revenues are expected to be \n significantly higher than the second quarter and prior periods.\n \n \n Cardax noted that its revenues for the second quarter of 2017 were \n approximately $66,000, which reflected a decrease from the first to \n second quarter primarily related to the initial stocking of ZanthoSyn™ \n in Hawaii GNC stores in Q1 that continued to support sales at GNC stores \n in Q2. The Company’s Q2 loss decreased moderately versus Q1 and, as \n expected, increased modestly from a year ago primarily due to ZanthoSyn \n sales and marketing activity.\n \n \n “We are pleased to see GNC same store sales of ZanthoSyn accelerate in \n the second quarter,” said Cardax CEO, David G. Watumull. “Physician \n recommendations and our outreach to GNC store personnel played a key \n role in this increase and position us well for continued growth.”\n \n \n Please refer to the Form 10-Q filed by the Company today for additional \n information.\n \n \n About Cardax\n \n \n Cardax devotes substantially all of its efforts to developing and \n commercializing safe anti-inflammatory dietary supplements and drugs. \n Cardax is initially focusing on astaxanthin, which is a powerful and \n safe naturally occurring anti-inflammatory without the side effects of \n currently marketed anti-inflammatories. The safety and efficacy of \n Cardax's products have not been directly evaluated in clinical trials or \n confirmed by the FDA.\n \n \n About ZanthoSyn\n \n \n ZanthoSyn™ is a physician recommended anti-inflammatory supplement for \n health and longevity that features astaxanthin with optimal absorption \n and purity. ZanthoSyn is sold online and in GNC stores. ZanthoSyn \n contains astaxanthin, which is Generally Recognized as S...